Loading stock research
Loading stock research…
$213.95
Observed · Source: Jupiter Tokens V2
Buy from your own wallet on Solana mainnet. You review and sign every transaction.
Checking whether mainnet purchases are available…
You sign in your own wallet. Ovelo never holds your keys or funds.
Daily closes of MRNA, the underlying share. A token’s rights, price and liquidity can differ from the share.
Research observed · Source: Yahoo Finance, Wikipedia (CC BY-SA)
What you would hold, where it trades and where these numbers come from.
Observed · Source: Jupiter Tokens V2
The company behind MRNA.
Moderna, Inc. ( mə-DUR-nə) (founded as ModeRNA Therapeutics, Inc.) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
Observed · Source: Company profile
Momentum from daily closes of the underlying share.
Computed from daily closes of the underlying share, not the token. Not a recommendation.
Close of · Source: Yahoo Finance daily closesStale
Reported financials. They describe the company, not the token’s market value.
| Item | Period end | Value |
|---|---|---|
| Revenue (annual) | 31 Dec 2025 | $1.92B |
| Revenue (annual) | 31 Dec 2024 | $3.20B |
| Revenue (annual) | 31 Dec 2023 | $6.75B |
| Revenue (annual) | 31 Dec 2022 | $18.88B |
| Net income (annual) | 31 Dec 2025 | −$2.82B |
| Net income (annual) | 31 Dec 2024 | −$3.56B |
| Net income (annual) | 31 Dec 2023 | −$4.71B |
| Net income (annual) | 31 Dec 2022 | $8.36B |
| Diluted EPS (annual) | 31 Dec 2025 | −7.26 USD/share |
| Diluted EPS (annual) | 31 Dec 2024 | −9.28 USD/share |
| Diluted EPS (annual) | 31 Dec 2023 | −12.33 USD/share |
| Diluted EPS (annual) | 31 Dec 2022 | 20.12 USD/share |
| Total assets (annual) | 31 Dec 2025 | $12.34B |
| Total assets (annual) | 31 Dec 2024 | $14.14B |
| Total assets (annual) | 31 Dec 2023 | $18.43B |
| Total assets (annual) | 31 Dec 2022 | $25.86B |
| Total debt (annual) | 31 Dec 2025 | $1.31B |
| Total debt (annual) | 31 Dec 2024 | $747.00M |
| Total debt (annual) | 31 Dec 2023 | $1.24B |
| Total debt (annual) | 31 Dec 2022 | $1.20B |
| Operating cash flow (annual) | 31 Dec 2025 | −$1.87B |
| Operating cash flow (annual) | 31 Dec 2024 | −$3.00B |
| Operating cash flow (annual) | 31 Dec 2023 | −$3.12B |
| Operating cash flow (annual) | 31 Dec 2022 | $4.98B |
| Free cash flow (annual) | 31 Dec 2025 | −$2.08B |
| Free cash flow (annual) | 31 Dec 2024 | −$4.06B |
| Free cash flow (annual) | 31 Dec 2023 | −$3.83B |
| Free cash flow (annual) | 31 Dec 2022 | $4.58B |
| Revenue (quarterly) | 30 Sept 2026 | $1.31B |
| Revenue (quarterly) | 30 Jun 2026 | $143.00M |
| Revenue (quarterly) | 31 Mar 2026 | $389.00M |
| Revenue (quarterly) | 31 Dec 2025 | $676.00M |
| Revenue (quarterly) | 30 Sept 2025 | $1.00B |
| Net income (quarterly) | 30 Sept 2026 | $162.00M |
| Net income (quarterly) | 30 Jun 2026 | −$782.00M |
| Net income (quarterly) | 31 Mar 2026 | −$1.34B |
| Net income (quarterly) | 31 Dec 2025 | −$826.00M |
| Net income (quarterly) | 30 Sept 2025 | −$200.00M |
| Diluted EPS (quarterly) | 30 Sept 2026 | 0.38 USD/share |
| Diluted EPS (quarterly) | 30 Jun 2026 | −1.97 USD/share |
| Diluted EPS (quarterly) | 31 Mar 2026 | −3.40 USD/share |
| Diluted EPS (quarterly) | 31 Dec 2025 | −2.11 USD/share |
| Diluted EPS (quarterly) | 30 Sept 2025 | −0.51 USD/share |
Reported dividends, splits and filings, each linked to its source.
No dividends, splits or filings were found.
Recent headlines about the company.